Replies to post #2406459 on BB's Stock Haven

[shakerzzz]

kool

[Abondanceinvest]

NEPT short term$__Sept 27,_2011_Healthcare_Conference

NEPTUNE TECH & BIORESOURCES ORD
Symbol U : NEPT
Recent Sedar Documents
Acasti Pharma to Present at JMP Healthcare Conference

2011-09-21 08:30 ET - News Release


LAVAL, Quebec, Sept. 21, 2011 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. ("Acasti") (TSX-V:APO), a Neptune Technologies & Bioressources Inc. ("Neptune") subsidiary, announces it will present at the 2011 JMP Securities Healthcare Conference :

The JMP Securities Healthcare Conference

Tuesday, September 27, 2011
12:00 PM Eastern Time
The St. Regis Hotel, New York
Speaker : Harlan Waksal, M.D., Executive Vice-President, Business & Scientific Affairs

For more information about this conference please visit : http://www.jmpg.com/jmpsecurities/about/conferences/

About Acasti Pharma Inc.

Acasti Pharma is developing a product portfolio of proprietary novel long-chain omega-3 phospholipids. Phospholipids are the major component of cell membranes and are essential for all vital cell processes. They are one of the principal constituents of High Density Lipoprotein (good cholesterol) and, as such, play an important role in modulating cholesterol efflux. Acasti Pharma's proprietary novel phospholipids carry and functionalize the polyunsaturated omega-3 fatty acids EPA and DHA, which have been shown to have substantial health benefits and which are stabilized by potent antioxidants. Acasti Pharma is focusing initially on treatments for chronic cardiovascular and cardiometabolic conditions within the over-the-counter, medical food and prescription drug markets.

About Neptune Technologies & Bioressources Inc.(Nasdaq:NEPT) (TSX-V:NTB)

Neptune is an industry-recognized leader in the innovation, production and formulation of science-based and clinically proven novel phospholipid products for the nutraceutical and pharmaceutical markets. The Company focuses on growing consumer health markets including cardiovascular, inflammatory and neurological diseases driven by consumers taking a more proactive approach to managing health and preventing disease. The Company sponsors clinical trials aimed to demonstrate its product health benefits and to obtain regulatory approval for label health claims. Neptune is continuously expanding its intellectual property portfolio as well as clinical studies and regulatory approvals. Neptune's products are marketed and distributed in over 20 countries worldwide.


BullsEye Share Thursday, September 22, 2011 9:44:37 AM
Re: Abondanceinvest post# 4941 Post # of 5443

Thanks AB> $30,000,000 LOI, nice gains in that price target you posted!!!